抗CD20单克隆抗体治疗寻常型天疱疮研究进展  

Anti- CD20 monoclonal antibody in the treatment of pemphigus vulgaris

作　　者：叶珊珊 王再兴[1] 

机构地区：[1]安徽医科大学第一附属医院皮肤性病科,合肥230000

出　　处：《国际皮肤性病学杂志》2017年第6期321-324,共4页International Journal of Dermatology and Venereology

基　　金：国家自然科学基金（81271747）

摘　　要：寻常型天疱疮是一种累及皮肤、黏膜，以泛发性水疱为特征的自身免疫性皮肤病，药物治疗寻常型天疱疮主要是通过抑制免疫系统，减少相关特异性抗体的产生，从而控制疾病的发展。目前糖皮质激素仍作为常规治疗的首选，而利妥昔单抗作为辅助治疗的一种抗CD20单克隆抗体，近年来已在寻常型天疱疮治疗中获得满意疗效。由于利妥昔单抗治疗可出现严重输液相关反应，增加感染风险，且价格昂贵、治疗累积时间长、易复发及耐药等缺点，临床上已减少了利妥昔单抗在寻常型天疱疮中的应用。新一代抗CD20单克隆抗体，克服了利妥昔单抗治疗的不良反应，有改善用药方式、减少治疗时间等优点，逐渐用于寻常型天疱疮治疗，新的研究成果给患者提供更多治疗选择。Pemphigus vulgaris is a kind of autoimmune skin disease involving the skin and mucous membranes and characterized by generalized blisters. Medicines exert their therapeutic effect on pemphigus vulgaris mainly by suppressing the immune system and reducing the production of related specific antibodies. At present, glueocortieoids still serve as the first-choice routine treatment. Rituximab, a kind of anti- CD20 monoclonal antibody, has shown satisfactory therapeutic effects in the adjuvant treatment of pemphigus vulgaris in recent years. However, the treatment with rituximab can cause severe transfusion- related reactions and increase the risk of infection. Because of the disadvantages of high price, long treatment duration, high recurrence risk and drug resistance, the clinical application of rituximab in the treatment of pemphigus vulgaris has been reduced. The new generation of anti-CD20 monoclonal antibody can overcome adverse reactions induced by rituximab treatment, improve medication approaches and reduce the treatment duration, so it has been gradually applied to the treatment of pemphigus vulgaris. In addition, new research results can provide more treatment options for patients with pemphigus vulgaris.

关 键 词：天疱疮 抗体 单克隆 治疗应用 抗CD20 利妥昔单抗 

分 类 号：R758.66[医药卫生—皮肤病学与性病学]